Global Graves Disease Treatment 麻豆原创 Growth 2025-2031

Publication ID:

LPI03257629

Publication Date:

March 4, 2025

Pages:

112

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Graves Disease Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Graves" disease is听an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Although a number of disorders may result in hyperthyroidism, Graves" disease is a common cause. Thyroid hormones affect many body systems, so signs and symptoms of Graves" disease can be wide ranging.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淕raves Disease Treatment Industry Forecast鈥� looks at past sales and reviews total world Graves Disease Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Graves Disease Treatment sales for 2025 through 2031. With Graves Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Graves Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Graves Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Graves Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Graves Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Graves Disease Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Graves Disease Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Graves Disease Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Anti-Thyroid Medication
Radioactive Iodine Therapy
Segmentation by Application:
Hospitals Pharmacies
Retail Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Abbott
Merck & Co
Pfizer, Inc
AbbVie, Inc
Mylan N.V
Allergan, plc
Novartis AG
Apitope
Amgen INC.
Sun Pharmaceuticals Industries LTD
Immunovant Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Graves Disease Treatment market?
What factors are driving Graves Disease Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Graves Disease Treatment market opportunities vary by end market size?
How does Graves Disease Treatment break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Graves Disease Treatment Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Graves Disease Treatment by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Graves Disease Treatment by Country/Region, 2020, 2024 & 2031
2.2 Graves Disease Treatment Segment by Type
2.2.1 Anti-Thyroid Medication
2.2.2 Radioactive Iodine Therapy
2.3 Graves Disease Treatment Sales by Type
2.3.1 Global Graves Disease Treatment Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Graves Disease Treatment Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Graves Disease Treatment Sale Price by Type (2020-2025)
2.4 Graves Disease Treatment Segment by Application
2.4.1 Hospitals Pharmacies
2.4.2 Retail Pharmacies
2.5 Graves Disease Treatment Sales by Application
2.5.1 Global Graves Disease Treatment Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Graves Disease Treatment Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Graves Disease Treatment Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Graves Disease Treatment Breakdown Data by Company
3.1.1 Global Graves Disease Treatment Annual Sales by Company (2020-2025)
3.1.2 Global Graves Disease Treatment Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Graves Disease Treatment Annual Revenue by Company (2020-2025)
3.2.1 Global Graves Disease Treatment Revenue by Company (2020-2025)
3.2.2 Global Graves Disease Treatment Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Graves Disease Treatment Sale Price by Company
3.4 Key Manufacturers Graves Disease Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Graves Disease Treatment Product Location Distribution
3.4.2 Players Graves Disease Treatment Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Graves Disease Treatment by Geographic Region
4.1 World Historic Graves Disease Treatment 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Graves Disease Treatment Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Graves Disease Treatment Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Graves Disease Treatment 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Graves Disease Treatment Annual Sales by Country/Region (2020-2025)
4.2.2 Global Graves Disease Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Graves Disease Treatment Sales Growth
4.4 APAC Graves Disease Treatment Sales Growth
4.5 Europe Graves Disease Treatment Sales Growth
4.6 Middle East & Africa Graves Disease Treatment Sales Growth
5 Americas
5.1 Americas Graves Disease Treatment Sales by Country
5.1.1 Americas Graves Disease Treatment Sales by Country (2020-2025)
5.1.2 Americas Graves Disease Treatment Revenue by Country (2020-2025)
5.2 Americas Graves Disease Treatment Sales by Type (2020-2025)
5.3 Americas Graves Disease Treatment Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Graves Disease Treatment Sales by Region
6.1.1 APAC Graves Disease Treatment Sales by Region (2020-2025)
6.1.2 APAC Graves Disease Treatment Revenue by Region (2020-2025)
6.2 APAC Graves Disease Treatment Sales by Type (2020-2025)
6.3 APAC Graves Disease Treatment Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Graves Disease Treatment by Country
7.1.1 Europe Graves Disease Treatment Sales by Country (2020-2025)
7.1.2 Europe Graves Disease Treatment Revenue by Country (2020-2025)
7.2 Europe Graves Disease Treatment Sales by Type (2020-2025)
7.3 Europe Graves Disease Treatment Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Graves Disease Treatment by Country
8.1.1 Middle East & Africa Graves Disease Treatment Sales by Country (2020-2025)
8.1.2 Middle East & Africa Graves Disease Treatment Revenue by Country (2020-2025)
8.2 Middle East & Africa Graves Disease Treatment Sales by Type (2020-2025)
8.3 Middle East & Africa Graves Disease Treatment Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Graves Disease Treatment
10.3 Manufacturing Process Analysis of Graves Disease Treatment
10.4 Industry Chain Structure of Graves Disease Treatment
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Graves Disease Treatment Distributors
11.3 Graves Disease Treatment Customer
12 World Forecast Review for Graves Disease Treatment by Geographic Region
12.1 Global Graves Disease Treatment 麻豆原创 Size Forecast by Region
12.1.1 Global Graves Disease Treatment Forecast by Region (2026-2031)
12.1.2 Global Graves Disease Treatment Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Graves Disease Treatment Forecast by Type (2026-2031)
12.7 Global Graves Disease Treatment Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Abbott
13.1.1 Abbott Company Information
13.1.2 Abbott Graves Disease Treatment Product Portfolios and Specifications
13.1.3 Abbott Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Abbott Main Business Overview
13.1.5 Abbott Latest Developments
13.2 Merck & Co
13.2.1 Merck & Co Company Information
13.2.2 Merck & Co Graves Disease Treatment Product Portfolios and Specifications
13.2.3 Merck & Co Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck & Co Main Business Overview
13.2.5 Merck & Co Latest Developments
13.3 Pfizer, Inc
13.3.1 Pfizer, Inc Company Information
13.3.2 Pfizer, Inc Graves Disease Treatment Product Portfolios and Specifications
13.3.3 Pfizer, Inc Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pfizer, Inc Main Business Overview
13.3.5 Pfizer, Inc Latest Developments
13.4 AbbVie, Inc
13.4.1 AbbVie, Inc Company Information
13.4.2 AbbVie, Inc Graves Disease Treatment Product Portfolios and Specifications
13.4.3 AbbVie, Inc Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 AbbVie, Inc Main Business Overview
13.4.5 AbbVie, Inc Latest Developments
13.5 Mylan N.V
13.5.1 Mylan N.V Company Information
13.5.2 Mylan N.V Graves Disease Treatment Product Portfolios and Specifications
13.5.3 Mylan N.V Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Mylan N.V Main Business Overview
13.5.5 Mylan N.V Latest Developments
13.6 Allergan, plc
13.6.1 Allergan, plc Company Information
13.6.2 Allergan, plc Graves Disease Treatment Product Portfolios and Specifications
13.6.3 Allergan, plc Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Allergan, plc Main Business Overview
13.6.5 Allergan, plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Graves Disease Treatment Product Portfolios and Specifications
13.7.3 Novartis AG Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Apitope
13.8.1 Apitope Company Information
13.8.2 Apitope Graves Disease Treatment Product Portfolios and Specifications
13.8.3 Apitope Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Apitope Main Business Overview
13.8.5 Apitope Latest Developments
13.9 Amgen INC.
13.9.1 Amgen INC. Company Information
13.9.2 Amgen INC. Graves Disease Treatment Product Portfolios and Specifications
13.9.3 Amgen INC. Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Amgen INC. Main Business Overview
13.9.5 Amgen INC. Latest Developments
13.10 Sun Pharmaceuticals Industries LTD
13.10.1 Sun Pharmaceuticals Industries LTD Company Information
13.10.2 Sun Pharmaceuticals Industries LTD Graves Disease Treatment Product Portfolios and Specifications
13.10.3 Sun Pharmaceuticals Industries LTD Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sun Pharmaceuticals Industries LTD Main Business Overview
13.10.5 Sun Pharmaceuticals Industries LTD Latest Developments
13.11 Immunovant Inc
13.11.1 Immunovant Inc Company Information
13.11.2 Immunovant Inc Graves Disease Treatment Product Portfolios and Specifications
13.11.3 Immunovant Inc Graves Disease Treatment Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Immunovant Inc Main Business Overview
13.11.5 Immunovant Inc Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.